



Money
or Down Markets

Make
In Up

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Charles Moskowitz Michael King

July 31, 2017

Market Strategies Guide to Successful Trading

**To subscribe to the Options Only Account Trades
Simply TEXT the word TRADES to the Number
and you will automatically be included.**

Market Strategies \$10,000 Options Account

Funds in Use \$ 342.00

Gain on closed Trades \$ 1,116.00

YTD: \$ 10,622.00

Long 6 LUV August 65 Calls

| MARKET LETTER INDEX | PG |
|---|----|
| Charles Moskowitz Discussion | 1 |
| \$10,000 Options Account | 2 |
| New Stock and Option Recommendations | 2 |
| Technical Information | 3 |
| Market Laboratory | 3 |
| Stock Positions 100,000 Acct | 4 |
| Week's Economic Numbers, Earnings Releases & Media Data | 6 |
| Fundamentals | 7 |
| Economics | 10 |
| Cycles | 13 |
| July Calendar | 15 |
| Lower Cap Stocks to Buy | 16 |
| Fundamental Stocks to Buy | 20 |

Charles Moskowitz Discussion

Week 30 was a gain of \$1116 taking our YTD gains over the 100% mark to \$10,622 or just over 106%. We started the week trading the SPY calls, followed by the puts and finally the calls again on Thursday. I closed out those calls on Thursday because I was traveling and out of touch Friday, and that turned out for the best since they collapsed into their expiration with the DJIA up and the NASDAQ and S&P500 down... all in all a very good week, even though we had losses on both the XBI and the first LUV position.

After watching the Sunday morning shows I am struck by the seemingly foolish and disjointed actions of the President and his House of Representatives. I have no idea how long these markets will be able to rely on the earnings being produced and ignore the haphazard actions of the executive and legislative branches. Surely should anything of a serious nature take place militarily the question of who's in charge and can we rely on them to make appropriate decisions and take the proper actions? It is a very dangerous world out there and there is nothing that changes sentiment faster than political or geopolitical actions.

The governmental changes made in the past weeks gone by put us on more of a military footing. I don't know if it's the right decision but while our representatives continue to do nothing on healthcare and spending issues, which will fall by the wayside in the face of any real-world problems.

The A.A.I.I. sentiment numbers became both less bullish *and* less bearish in favor of more neutral. It is really unusual in my very long term participation in the markets to have these kind of readings.

Mike's fundamental section starting on page 7 and economic discussion on page 9 show strength in many of our biggest industrials and consumer confidence seems supportive of further gains, but take a look at the D.J. Transportation, down over 3% on Thursday and not really heavily supported until 8960-9022, and still showing a slightly overbought reading here at 9227.

All that said, I will look at SPY trades in either direction as long as risk profiles meet the same standards as the last several days and weeks... **CAM**

All trades were based on your participation in the texting service to receive updates.

| DATE | | PRICE | COST | PROCEEDS | RESULTS |
|-------|---|-------|------|----------|-----------------|
| 07/27 | Sold 5 SPY July 28 th 247 Calls | 0.44 | | 220 | 125 Gain |
| 07/27 | Sold 5 SPY July 28 th 247 Calls (100% profit Rule) | 0.38 | | 190 | 95 Gain |
| 07/27 | Bought 10 SPY July 28 th 247.00 Calls | 0.19 | 190 | | |
| 07/27 | Sold 8 SPY July 28 th 247.50 Puts | 0.73 | | 584 | 392 Gain |
| 07/27 | Sold 7 SPY July 28 th 247.50 Puts (100% Profit Rule) | 0.48 | | 336 | 168 Gain |
| 07/27 | Bought 15 SPY July 28 th 247.50 Puts | 0.24 | 360 | | |
| 07/27 | Sold 6 XBI August 83 Calls (50% Loss Rule) | 0.44 | | 264 | 264 Loss |
| 07/27 | Bought 6 LUV August 60 Calls | 0.57 | 342 | | |
| 07/26 | Sold 10 SPY July 28 th 247.50 Puts | 0.55 | | 550 | 70 Gain |
| 07/26 | Bought 10 SPY July 28 th 247.50 Puts | 0.48 | 480 | | |
| 07/25 | Bought 6 XBI August 83 Calls | 0.88 | 528 | | |
| 07/25 | Sold 5 SPY July 28 th 247 Calls | 1.09 | | 545 | 275 Gain |
| 07/25 | Sold 6 LUV August 65 Calls (50% Loss Rule) | 0.30 | | 180 | 180 Loss |
| 07/25 | Sold 5 SPY July 28 th 247 Calls | 1.41 | | 705 | 435 Gain |
| 07/24 | Bought 10 SPY July 28 th 247 Calls | 0.54 | 540 | | |
| 07/19 | Bought 6 LUV August 65 Calls | 0.60 | 360 | | |

NEW TRADES OPTIONS ACCOUNT

- (1) BUY 4 ADM AUGUST \$41 CALLS @ \$ 1.20
- (2) BUY 10 BBRY AUGUST \$ 9.50 CALLS @ \$ 0.36

NEW TRADES \$ 100 000 ACCOUNT:

- (1) BUY 8 ADM AUGUST \$41 CALLS @ \$ 1.20
- (2) BUY 20 BBRY AUGUST \$ 9.50 CALLS @ \$ 0.36

MARKET LABORATORY - WEEKLY CHANGES

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect

| | | | | | |
|--|--|--|---|---|---|
| Dow 21,830.31 +250.24 +1.16% | Nasdaq 6374.68 -13.08 -0.20% | S&P 500 2472.10 -0.44 -0.02% | Transportation 9227.07 -244.20 -2.58% | Russell 2000 1429.26 -6.58 -0.46% | Nasdaq100 5921.52 +83.44 +1.43% |
| Gold (spot) 1268.40 +14.10 +1.1% | Silver Sept 16.457 +0.524 +3.3% | Crude July 49.71 +3.94 +0.9% | Heating Oil 1.6409 +0.0338 +2.1% | Unleaded Gas 1.6458 +0.0261 +1.6% | Natural Gas 2.941 -0.026 -0.9% |
| VIX 10.29 +0.93 +9.9% | Put/Call Ratios S&P 100 107/100's -1/100's | Put/Call Ratios CBOE Equity 72/100's +14/100's | Bonds 153-06 +0-15 2.897%0-05.4% | 10 Yr. Note 125-30 +0-6 2.29%-0305% | Copper 2.7225 +0.310 +11.5% |
| CRB Inflation Index 182.12 +5.46 +3.1% | Barron's* Confidence 76.0 +0.3 | S&P100 1087.74 +4.61 +0.43% | 5 YR Note 117-27 -0+11 1.84%-0.025% | Dollar 93.34 -0.52 -0.6% | DJ Utilities 724.06 -1.42 -0.20% |
| AAll Confidence Index Average | Bullish 34.5% -1.0% 38.4% | Bearish 24.3% -1.5% 30.30% | Neutral 41.2% +2.5% 30.96% | M1 Money Supply +7.67% July 17 th | M2 Money Supply +5.63% July 17 th |

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect * Component Change is in the Confidence Index

| | SUPPORT | RESISTANCE |
|--------------|---------|------------|
| S&P 500 | 2434 | 2500 |
| NASDAQ (QQQ) | 140.01 | 145.50 |
| Trans | 89.20 | 94.30 |
| DOW | 21,350 | 21,880 |
| TLT | 122.20 | 126.80 |

Each Stock is allocated a theoretical \$ 5,000 share of the portfolio

| | Purchase Price | Purchase Date | Stop/Loss | Price/Date Sold | Profit/(\$ 920Los) |
|------------|----------------|---------------|-----------|-----------------|--------------------|
| SCO 250 | 42.48 | 07/06 | | 47.34 07/10 | \$ 1215 |
| BBRY 400 | 11.21 | 06/07 | | | |
| GLYC 400 | 12.66 | 06/01 | | | |
| HL 500 | 5.72 | 06/01 | | | |
| GSAT 1500 | 2.30 | 05/18 | | | |
| SLV 300 | 15.78 | 05/15 | | | |
| AGQ 150 | 40.39 | 04/07 | | | |
| NUGT 75 | 35.68 | 03/13 | | | |
| RWM 100 | 50.60 | 11/21 | | | |
| SPXU 200 | 22.88 | 11/14 | | | |
| AMBA 100 | 63.75 | 10/13 | | | |
| MOS 200 | 27.53 | 05/02 | | | |
| EYES 500 | 5.04 | 04/04 | | | |
| EYES 1000 | 6.49 | 12/28 | | | |
| TWTR 200 | 28.51 | 10/28 | | | |
| MOS 100 | 43.55 | 08/14 | | | |
| HL 500 | 3.95 | 05/03 | | | |
| SAN 600 | 8.40 | 12/16 | | | |
| TEXQY 200 | 6.56 | 7/11 | | | |
| REPR* 5000 | 0.22 | 10/22/12 | | | |

Recommendations will be both listed in this letter and texted to members. Previous closed out trades can be seen on each preceding weekly market letter. X means stop loss

July24th;17th;10th;3rd;June26th;19th;12th;5th;May9th;22nd;15th;8th;1st;Aprilth;24th;17th;10th;3rd;March7th;20th;13th;6th

SCO means stop close only

Additional New Options Trades: will be texted

Large Account: Additional trades and stop losses will be Texted and E-Mailed

The new number has been provided. Call Dave Rodgers if there are problems at (832) 236- 3640.

Or Mike King 702 650 3000; Charles Moskowitz 617 827 1296

There were nine closed out options positions last week gaining \$2,207.00 in options trading. There was one closing stock trade: the sale of 200 shares of SCO at \$ 40.90 which lost \$280.00. There is one remaining long option position, the 12 LUV August \$60 Calls bought at \$0.57 costing \$684.00. The net gain for the week was \$1,927.00. The total requirement for options is \$684.00. The options expire on the third Friday of each Month unless otherwise posted. The Stock table has the following 19 positions: AGQ, BBRY,EYES (2), GLYC, GSAT,HL (2), MOS (2), NUGT, REPR, RWM, SAN, SCO,SLV, SPXU TEXQY, TWTR,

:

The options call for a \$ 2,207 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically. Money management is based on a hypothetical \$100,000.00.

The 19 stock positions would cost \$79,338.00. The open long options position; the LUV August \$60 Calls require \$684.00; when combined with the stock requirement of \$79,338.00 equals \$80,022.00 which leaves excess cash of \$19,978.00.

YEAR TO DATE the \$100,000 Account has had 142 closed out trades between stocks, options and covered writes versus stock positions. Of those, 96 were gains and 46 were losses. Gains to date equal \$51,319.00; losses equal \$18,689.00, for a net gain of \$32,630.00. This number does not take into consideration commissions or open gains or losses.

These figures are approximate and there might be errors. The trading is hypothetical and we do not count commission costs.

Previous Week's Recommendations and Rules for the \$ 100,000 account

- **Text UPDATES to number provided**
- All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated.
- When the option has doubled sell half the position.
- Stop Loss protection is half if Option trades above 50 Cents or offered with each trade.
- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price
- Subscribers can follow us on Twitter or call 702 650 3000 for up to date information.

Note: Closed out stock and option positions can be found in previous weekly market letters: Such as

July 24th;17th;10th; 3rd;June 26th;19th; 12th; 5th; May 29th;22nd;15th;8th; 1st; April 24th; 17th;10th;3rd;Mar 27th;20th

| Option | COST | Date | Sold | Date | Profit/(Loss) |
|---|-----------------------------|----------|--|----------------------------------|--------------------------|
| SPYJuly28th247 20 lots | <u>Calls</u> <u>0.19</u> | 07/27/17 | 0.38(100% Profit Rule Sold Half 0.44 Sold Balance later same Day | 07/27/2017 07/27/2017 | \$ 190 \$ 250 |
| SPYJuly28th247.50 30 lots | <u>Puts</u> <u>0.24</u> | 07/27/17 | 0.48 (100% Profit Rule 0.73 Sold Balance later same Day | 07/27/2017 07/27/2017 | \$ 360 \$ 735 |
| SPYJuly28 th 247.50 20 lots | <u>Puts</u> <u>0.48</u> | 07/26/17 | 0.55 | 07/26/2017 | \$ 140 |
| XBI Aug 83 12 lots | <u>Calls</u> <u>0.88</u> | 07/25/17 | 0.44 (50% Loss Rule) | 07/27/2017 | (\$ 528) |
| SPY July28th 247 20 lots | <u>Calls</u> <u>0.54</u> | 07/24/17 | 1.41 Sold Half 1.09 Sold Balance | 07/25/2017 07/25/2017 | \$ 870 \$ 550 |
| LUV Aug 65 12 lots | <u>Calls</u> <u>0.60</u> | 07/19/17 | 0.30 (50% Loss Rule) | 07/25/2017 | (\$ 360) |

This week's Economic Numbers and Earnings Releases: Before the Open on top of the Row; After the Close below the Economics information and News releases: Space is limited:

| | |
|------------------|--|
| MONDAY | <p>CNA Financial CNA (0.76 vs 0.77) DANA Inc DAN (0.51 vs 0.53) Mercury General MCY (0.50 vs 0.88) Roper ROP (2.22 vs 1.56) Sanofi SNY (1.30)</p> <p>09:45 hrs Chicago PMI July (60 vs 65.7) 10:00 hrs Pending Home Sales June (1.1% vs -0.8%)</p> <p>Altaba AABA (0.15 vs 0.09) Amkor AMKR (0.12 vs 0.02) Green Plains GPRE (-0.06 vs 0.21) Health south HLS (0.68 vs 0.69) Olin OLN (0.19 vs 0.24) Owens-Illinois OI (0.67 vs 0.65) Pandora P (-0.24 vs -0.12) Silicon Motion SIMO (0.72 vs 0.86)</p> |
| TUESDAY | <p>Air Products APD (1.59 vs 1.92) Archer-Daniels ADM (0.52 vs 0.41) BP 0.05 vs 0.23 Cummins CMI (2.56 vs 2.40) Eaton ETN (1.16 vs 1.07) Ecolab ECL (1.12 vs 1.08) Emerson EMR 0.68 vs 0.80 Fresenius Medical FMS (1.05 vs 0.96) Honda HMC 88.87 vs 96.93) IGT (0.32 vs 0.43) Pfizer PFE 0.66 vs 0.64 Phillips 66 PSX (1.03 vs 0.94) Sony SNE (56.17 vs 16.44) Sprint S (-0.05 vs -0.08) Xerox XRX (0.80 vs 0.26)</p> <p>08:30 hrs Personal Income June (0.3% vs 0.4%) 08:30 hrs Personal Spending June (0.1% vs 0.1%) 08:30 hrs PCE Prices - CORE June (NA vs -0.1%) 10:00 hrs Construction Spending June (0.5% vs 0.0%) 10:00 hrs ISM Index July (56.2 vs 57.8) 14:00 hrs Auto Sales July (NA vs 4.27MlnUnits) 14:00 hrs Truck Sales July (NA vs 8.77Mln Units)</p> <p>Apple AAPL (1.57 vs 1.42) Assurant AIZ (1.60 vs 1.42) Community Health CYH (-0.02 vs 0.09) DaVita DVA 0.93 vs 1.01 Devon Energy DVN 0.33 vs 0.06 EOG 0.11 vs -0.38 Hanesbrands HBI 0.53 vs 0.51 Ternium TX 1.04 vs 0.78 Voya Financial VOYA 0.85 vs 0.79</p> |
| WEDNESDAY | <p>AutoNation AN (0.98 vs 1.08) Bunge BG (0.16 vs 0.79) Cardinal Health CAH 1.25 vs 1.14 Delphi Auto DLPH (1.65 vs 1.59) Dominion Energy D (0.67 vs 0.71) Humana HUM 3.08 vs 2.30 Molson Coors TAP (2.10 vs 1.11) Mondelez MDLZ 0.46 vs 0.44 Southern SO (0.71 vs 0.74) Time Warner TWX (1.19 vs 1.29) Veritiv VRTV 0.93 Vulcan Mat VMC 1.21 v 0.90</p> <p>07:00 hrs MBA Mortgage Applications Index 07/29 (NA vs 0.4%) 08:15 hrs ADP Employment Change July (187K vs 158K) 10:30 hrs Crude Inventories 07/29 (NA vs -7.2Mln Bbls)</p> <p>American Int'l AIG (1.20 vs 0.98) CenturyLink CTL 0.49 vs 0.63 Chemours CC 0.85 vs 0.27</p> |
| THURSDAY | <p>Aetna AET 2.35 vs 2.21 Allergan AGN 3.92 vs 3.35 AmerisourceBergen ABC 1.38 vs 1.37 Arrow Elec ARW 1.77 vs 1.65 Avon AVP 0.07 vs 0.07 CDW 1.02 vs 0.93 Canadian Nat Resources CNQ 0.23 vs 0.16 Church and Dwight CHD 0.39 vs 0.85 CLX 1.49 v1.30</p> <p>07:30 hrs Challenger Job Cuts July (NA vs -19.3%) 08:30 hrs Initial Claims 07/29 (242K vs 244K) 08:30 hrs Continuing Claims 07/22 (NA vs 1964K) 10:00 hrs Factory Orders June (+2.9% vs -0.8%) 10:00 hrs ISM Services July (56.9 vs 57.4) 10:30 hrs Natural Gas Inventories 07/29(NA vs 17 bcf)</p> <p>Activision Blizzard ATVI 0.30 vs 0.45 Alleghany Corp Y 7.95 vs 4.99 Fluor FLR 0.59 v 0.72</p> |
| FRIDAY | <p>Aon AON 1.44 vs 1.39 CIGNA CI 2.48 vs 1.98 Cooper Tire CTB 0.74 vs 1.27 Newell NWL (0.87 vs 0.78) Toyota TM (153 vs 91) Well Care WCG 2.24 vs 2.23</p> <p>08:30 hrs Nonfarm Payrolls July (181K vs 222K) 08:30 hrs Nonfarm Private Payrolls July (175K vs 187K) 08:30 hrs Unemployment Rate July (4.3% vs 4.4%) 08:30 hrs Avg. Hourly Earnings July (0.3% vs 0.2%) 08:30 hrs Average Workweek July (34.5hrs vs 34.5hrs) 08:30 hrs Trade Balance June (-44.9B vs -\$46.5B)</p> <p>The U.S. Oil Rig Count increased by 2 Rigs to 766. The Nat Gas Rig count increased by 6 to a total of 192, making a total rig count 958. Crude closed higher at \$49.71 up \$3.94 or +0.9%. Natural Gas closed the week falling \$ 0.026 or -0.9% at \$ 2.94.</p> |

FUNDAMENTALS

The Dow Jones Industrials (21,830.31 + 250.24 or + 1.2% for the week, was the best performing index after being the worst the previous week. Boeing (BA: \$241.27) + \$29.13 or + 13.7% was the catalyst and by far the leading stock for the week. Boeing posted its biggest one-day gain last Wednesday after beating earnings expectations and raising full year guidance to almost \$10/share. Other leaders were Verizon Communications (VZ: \$47.94) + \$ 3.71 or + 8.4%; Caterpillar (CAT: \$ 114.10) + \$ 7.51 or + 7.1%; Wal-Mart Stores (WMT: \$79.81) + 4.8% and Chevron Corp (CVX: \$ 108.12) + \$4.87 or + 4.7%. The biggest decliners were 3M Company (MMM: \$ 199.72) - \$ 11.44 or - 5.4% and United Technologies falling (UTX: \$118.87) - \$4.62 or - 3.7%.

The S&P fell 0.13% on Friday to close the week with a loss of 0.44 or - 0.02%, after making new all-time highs the previous week. Seagate Technology STX was a huge loser off \$6.97 or -17.6%; Interpublic Group of Companies (IPG: \$ 21.61) - \$ 3.90 or down 15.3%; Flowserve Corp (FLS: \$ 41.30) - \$ 4.93 or - 10.7%; Universal Health Services UHS: \$111.50 off \$12.92 or - 10.4% and Western Digital Corp (WDC: \$ 84.97) - \$ 9.85 or - 10.4%; Envision Healthcare Corp (EVHC: \$ 56.16) - \$ 6.45 or - 10.3%; and Johnson Controls (JCI: \$ 39.64)- \$4.55 or -10.3%..

The Nasdaq Composite (6374.68) - \$13 or - 0.2% had a small loss of less than a percent after gaining 5.4% the previous two weeks.

The Dow Jones Transportation Average, the DJ 20 fell 244 points or -2.6%, continuing its descent off more than 500 points after making new all-time highs July 14th at 9742.76. Southwest Airlines, LUV led the descent off \$3.72 or 6.2%.

| Index | Started Week | Ended Week | Change | % Change | YTD % |
|--------------|--------------|------------|---------|----------|-------|
| DJIA | 21580.07 | 21830.31 | 250.24 | 1.2% | 10.5 |
| Nasdaq | 6387.75 | 6374.68 | -13.07 | -0.2% | 18.4 |
| S&P 500 | 2472.54 | 2472.10 | -0.44 | 0.0% | 10.4 |
| Russell 2000 | 1435.84 | 1429.26 | -6.58 | -0.5% | 6.4 |
| DJT | 9471.27 | 9227.07 | -244.20 | -2.6% | 2.0 |

US Dollar (DXYO: 93.32) -\$2.31 or -2.4%. The dollar collapsed to its lowest level since June 2016. The weak greenback is bullish for exports. The DJT is the weakest of all stock indexes.

Volatility (VIX: \$10.29 + 9.9%) Volatility reversed closing much higher for the week.

CBOE OEX Volatility Index (VXO-X 8.26) +0.49 or +6.3% after making a new all-time low at 6.32, the index reversed closing almost 200 points off the low. The 6.32 is the lowest number ever recorded for the index. The reversal is an example of uncertainty making stock market trading more hazardous.

The UVXY, (\$ 30.19) or + \$ 0.40 (4 for 1 equivalent) for the old shares, which reached the highest level since January 12th.

The U.S. Oil Fund (USO: \$10.17) +\$ 0.83 or +8.9% got support as it rallied above its 50 day price moving average.

Semiconductors (SMH: \$ 86.35) -1.12 or 1.3% : The 85 level is approximately the 50 day moving average and an important level that must hold if this bull market is to continue. The action looks topky.


Gold (GLD: \$ 120.69 +\$ 1.43 or +1.2% Found support at the \$114.80 level which is also a lower Bollinger Band support level. And now is into resistance at the upper Bollinger Band at about the 121.00 level.

The GDX, the VanEck Gold Miners ETF (GDX: 22.91) + \$0.50 or +2.2% Found support at a double bottom at the \$ 21.00 level, and now has approached resistance at the declining critical 200 day moving average at just above \$ 23.00.

Alibaba Group Holding Limited (NYSE: [BABA](#): \$157. 56) +5.67 or + 3.7% possibly making a double top at the \$160 level, after having rallied all year since December 30th. BABA is a market retailing leader. It rebounded nicely from oversold conditions remaining solidly bullish. Our original buy recommendation on April 11th was \$111.00/share.

Amazon (AMZN: \$1020.04) -5.63 or -0.5%: Climaxed at \$1083.31 and then dropped 60 points.

Crude OIL (\$49.71) +3.94 or +0.9%: Rebounded from oversold conditions with \$50 resistance.



While I am not a "dyed in the wool" adherent of seasonal moves you cannot ignore the end of summer lack of liquidity and [usual bearish trend](#) that come out of the lower volume days as vacations wind down. There are all sorts of crosscurrents that take place [from the good](#) earnings and last weeks' first look at Q2 GDP (on track for 2%) [which](#) lend weight to continued gains in the last quarter. But, first we will have to see if these markets can consolidate gains without the breaks associated with the "first elected Republican."

Either way we can have a solid Q4, but from what level becomes the question. *CAM*

ECONOMICS

GDP for the second quarter was estimated to have increased at a seasonally adjusted annual rate of 2.6% (Briefing.com consensus 2.8%) following a downwardly revised 1.2% increase (from 1.4%) for the first quarter. Real final sales, which exclude the change in private inventories, were also up 2.6%.

The largest contributors to the increase in Q2 GDP were personal consumption expenditures (1.93 percentage points), gross private domestic investment (+0.34 percentage points), and net exports (+0.18 percentage points). The change in private inventories subtracted just 0.02 percentage points from Q2 GDP growth.

Government spending added 0.12 percentage points, with federal spending contributing 0.15 percentage points and state and local spending subtracting 0.02 percentage points. Defense spending, which contributed 0.20 percentage points, accounted for the entirety of the positive contribution from federal spending.

The key takeaway from the Q2 GDP report, then, is that the average for the first half of 2017 was subpar at 1.9%, which should continue to keep any concerns about the prospect of a near-term rate hike from the Fed under wraps.


| Category | Q2 | Q1 | Q4 | Q3 | Q2 |
|-----------------------|-----------|-----------|-----------|-----------|-----------|
| GDP | 2.6% | 1.2% | 1.8% | 2.8% | 2.2% |
| Inventories (change) | -\$0.3B | \$1.2B | \$63.1B | \$17.6B | \$12.2B |
| Final Sales | 2.6% | 2.7% | 0.7% | 2.6% | 2.9% |
| PCE | 2.8% | 1.9% | 2.9% | 2.8% | 3.0% |
| Nonresidential Inv. | 5.2% | 7.1% | 0.2% | 3.4% | 3.3% |
| Structures | 4.9% | 14.8% | -2.2% | 14.3% | 0.5% |
| Equipment | 8.2% | 4.4% | 1.8% | -2.1% | -0.6% |
| Intellectual Property | 1.4% | 5.8% | -0.4% | 4.2% | 11.1% |
| Residential Inv. | -6.8% | 11.1% | 7.1% | -4.5% | -4.8% |
| Net Exports | -\$614.9B | -\$622.2B | -\$631.1B | -\$557.3B | -\$572.4B |
| Export | 4.1% | 7.3% | -3.8% | 6.4% | 2.8% |
| Imports | 2.1% | 4.3% | 8.1% | 2.7% | 0.4% |
| Government | 0.7% | -0.6% | 0.2% | 0.5% | -0.9% |
| GDP Price Index | 1.0% | 2.0% | 2.0% | 1.4% | 2.4% |



Source: Bureau of Economic Analysis; updated 07/28/17


Briefing.com

The GDP Price Deflator was up just 1.0% below the Briefing.com consensus of 1.3% following an upwardly revised 2.0% increase (from 1.9%) for the first quarter.




Source: Bureau of Economic Analysis; updated 07/28/17

Briefing.com



Source: Bureau of Economic Analysis; updated 07/28/17

Briefing.com



Source: Bureau of Economic Analysis; updated 07/28/17

Briefing.com

The **Consumer Confidence** Index increased to 121.1. The Briefing.com consensus expected 116.8 in July from a downwardly revised 117.3 (from 118.9) in June.


The **Present Situation Index** increased from 143.9 to 147.8, which is a 16-year high.

The **Expectations Index** rose from 99.6 to 103.3

Despite an improved outlook for the labor market, consumers were not as upbeat, the report said, about their income prospects as in June. The percentage of consumers expecting an improvement in their income declined from 20.9% to 20.0%, while the proportion expecting a decline increased from 9.3% to 10.0%.

The key takeaway from the report is that the July enthusiasm has bolstered the economy and helped improve sentiment for current conditions as well as the short-term outlook.

| Category | JUL | JUN | MAY | APR | MAR |
|---|-------|-------|-------|-------|-------|
| Conference Board | 121.1 | 117.3 | 117.6 | 119.4 | 124.9 |
| Expectations | 103.3 | 99.6 | 102.3 | 105.4 | 112.3 |
| Present Situation | 147.8 | 143.9 | 140.6 | 140.3 | 143.9 |
| Employment ('plentiful' less 'hard to get') | 16.1 | 13.6 | 11.7 | 10.9 | 12.8 |
| 1 year inflation expectations | 4.6% | 4.6% | 4.7% | 4.7% | 4.7% |



Durable Goods Orders for June surged 6.5% (Briefing.com consensus +2.9%) on the back of a robust gain in transportation equipment orders (+19.0%) that was powered by a 131.2 % increase in nondefense aircraft orders.


Excluding transportation, new orders for durable goods were up a more modest 0.2% (Briefing.com consensus +0.5%). On a year-over-year basis, new orders for durable goods are up 5.0%. Excluding transportation, they are up 4.9%.

Excluding transportation, the pockets of order strength in June were found in primary metals (+0.1%), fabricated metal products (+0.7%), machinery (+0.2%), and communications equipment (+1.3%)

The main pockets of order weakness in June were motor vehicles and parts (-0.6%), computers and electronic products (-0.3%), and electrical equipment, appliances and components (-1.7%).

The key takeaway from the report is that orders for nondefense capital goods excluding aircraft -- a proxy for business investment -- were down 0.1%. Shipments of those same goods, though, were up 0.2% on the heels of a 0.4% increase in May, which will be a positive input for Q2 GDP forecasts.

| Category | JUN | MAY | APR | MAR | FEB |
|--|-------|-------|-------|-------|--------|
| Total Durable Orders | 6.5% | -0.1% | -0.8% | 2.4% | 1.4% |
| Less Defense | 6.7% | 0.4% | -0.8% | 1.1% | 1.9% |
| Less Transport | 0.2% | 0.6% | -0.4% | 0.9% | 0.3% |
| Transportation | 19.0% | -1.6% | -1.6% | 5.4% | 3.6% |
| Capital Goods | 19.0% | -0.9% | -1.9% | 4.7% | 2.3% |
| Nondefense | 21.0% | -0.2% | -2.4% | 1.9% | 4.2% |
| Nondefense/non aircraft (core cap goods) | -0.1% | 0.7% | 0.3% | 0.0% | 0.1% |
| Defense Cap Goods | 3.8% | -6.2% | 1.7% | 30.6% | -12.7% |



Source: Census Bureau; updated 07/27/17

Briefing.com


CYCLES

August Almanac: Weak Early and Late, Brief Strength Mid-Month

Money flows from harvesting made August a great stock market month in the first half of the Twentieth Century. It was the best month from 1901 to 1951. In 1900, 37.5% of the population was farming. Now that less than 2% farm, August is amongst the worst months of the year. It is the worst DJIA and S&P 500 month from 1988-2016 with average declines of 1.3% and 1.0% respectively. August is also the worst month for NASDAQ (-0.3%), Russell 1000 (-0.9%) and Russell 2000 (-0.7%) over the same time period. In post-election years since 1953, Augusts' rankings are little changed: #12 DJIA, #11 S&P 500, #11 NASDAQ (since 1973), #11 Russell 1000 and #10 Russell 2000 (since 1981).

The first nine trading days of the month have exhibited weakness while mid-month is strongest. Note the bullish cluster from August 15-17. The end of August tends to get whacked as traders evacuate Wall Street for the summer finale. The last five days have suffered in 13 of the last 21 years with the S&P 500 up only five times on the next to last day in the past 21 years. In the last 21 years, the last five days of August have averaged losses of: Dow Jones Industrials, -1.0%; S&P 500, -0.9%; NASDAQ, -0.6% and Russell 2000, -0.02%.

On Monday of expiration the Dow has been up 15 of the last 22 times with four up more than 1%, while on expiration Friday it has been down six of the last seven years (-3.1% in 2015). Expiration week as a whole is down slightly more than half the time since 1990, but some of the losses have been steep (-2.6% in 1990, -2.3% in 1992, -4.1% in 1997, -4.0% in 2011, 2.2% in 2013 and 5.8% in 2015). The week after expiration is mildly stronger up 16 of the last 27.



The above chart is signaling seasonal bearishness for stocks. This poor seasonal performance has occurred since 1987. The Asian currency crisis and the Long-Term Capital Management hedge fund debacle ending August 31, 1998 as the DJIA fell 6.4% that day. DJIA dropped a record 1344.22 points for the month, off 15.1%, which is the second worst monthly percentage DJIA loss since 1950. Saddam Hussein triggered a 10.0% slide in August 1990. The best DJIA gains occurred in 1982 (11.5%) and 1984 (9.8%) as bear markets ended. Sizeable losses in 2010, 2011, 2013 and 2015 of over 4% on DJIA have widened Augusts' average decline.

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.46)

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and the latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HlGH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

RMS" or the "Company" is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing™ and RMS HlGH-Flo Subcutaneous Safety Needle Sets™ to be used with either the FREEDOM60® or the FreedomEdge® Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from **ContraCare** GmbH, a leader in Germany for **Contract Management (reimbursement) Services and Managed Care (homecare) solutions**. The App is now available for iOS in the Apple™ Store and Android in the Google™ Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HlGH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$10.98)

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 66.3% versus the Dow Jones +8.3%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science

divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court. Enzo Biochem closed today, June 30, at \$11.04. For the quarter it was up 31.9% and for the first half it was up 59.08%. The Standard and Poor 500 closed at 2,423 up 2.57% for the quarter and 8.24% for the first half. The stock has been acting great and I hope it continues for the second half of the year.

A quick rundown of the year so far: The Company announced its fiscal 3rd quarter a few weeks ago. For the first time in many years they showed a breakeven third quarter and no cash burn. They actually increased the cash position by \$200,000. I see no reason that this performance will not continue for the rest of the year.

Three new AmpProbe products were announced as being approved by the New York Department of Health with more approvals anticipated over the near future. As was announced in the conference call on June 11th; the Company anticipates a product rollout to the market in early fall. They will expand their market to include New England and the Atlantic States.

With Enzo now being included by Cigna for reimbursement I would expect to start seeing the top line numbers for Revenues ramp up. The Company also hopes to have blanket approval in all states by the end of the year. In the 2nd quarter conference call a question was asked by the Rodman Renshaw analyst about Alequel for treatment of Crohn's disease. The response by Mr. Weiner was that there are discussions with Hadassah Hospital where the trials were held a few years ago. Crohn's and Uveitis are not in the stock price and if any news comes out on either of these products I feel it would have a very positive effect on the price of the stock.

The stock should consolidate its gains over the near term and as product approvals come in and AmpProbe moves into the market, the stock price could move to \$15. Positive news on the Therapeutics could move it much higher. There is very little stock available Institutional ownership is stated to be 61.47% and the Officers, Directors and insiders would be an additional 15% to total 76% of the 46 million shares or 35 million shares leaving 11 million in the float. Enzo's market cap is now over \$500 million which will make more Institutions that have a minimum market cap of \$500 million to be buyers of a stock. Barring any unforeseen events I think we should have a very good second half of the year.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company passed the \$ 500 million dollar market cap when the stock price reached (\$10.63) they qualified for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO 6.00*

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences

entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is “bottlenecked” by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“*psi*”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“*DNA*”), ribonucleic acid (“*RNA*”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“*PULSE*”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System (“*PCT SPS*”).

The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- *Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;*
 - *Pathogen inactivation (useful in vaccine development, infectious disease research, and more);*
 - *Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);*

●and immunodiagnostics (useful in the development and detection of biomarkers).

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.

NIGHT FOODS (NGTF)

Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or “bites”

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies,

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We’ve seen it happen with low-carb, we’ve seen it happen with gluten-free. Can it happen with nighttime snacking as well?

Leo Motors (LEOM: \$ 0.13)* has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.

Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.

In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo’s power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.

Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar.

Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.

Skinvisible (SKVI: \$ 0.02)*

Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI), is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

Fundamental Analysis: Stocks To Buy with Stops: Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. As indicated on the table below, balance is critical. And we have exited most positions. Alibaba has made a great deal of points. We are raising the stop loss price. We have no position in Alcoa AA. If long use a close below \$32 as a risk point. Flushing Financial FFIC fell to and held the 50 day price moving average on March 3rd, which was a buying opportunity. We would stay long the Flushing Financial. We are not involved with Bristol Myers. Hecla Mining is a buy as long as it is above the 13 day price moving average. We took profits on ENZ but still want to be long at lower prices. The HDGE may finally be oversold and relevant at this time. It is a decent long or offset against portfolio positions as long as it holds above \$ 8.63.

| | Name | Business Description | PE | P/S | MV mln | Price | Buy or Sell Limit | Stop Loss Or offset |
|------|---------|---|-------|-------|-----------|--------|-----------------------------------|--|
| BABA | Alibaba | Largest on-line book in China; more of a retailer than Amazon | 50.67 | 13.21 | 275.5B | 157.56 | Bought @ \$ 111 on 4/7/17 opening | Take Profits now using \$ 160 as dbl top |

| | | | | | | | | |
|------|-------------------------------|---|-----|------|--------|--|---|--|
| AMZN | Amazon | Catalog & Mail Order | 189 | 2.90 | 394B | 1025.67 stopped out | Sold on stop | No position |
| SIMO | Silicon Motion | Semiconductor solutions for mobile storage and communications | 9.7 | 2.5 | 1.39B | 41.55 Stopped out 49.40 | Bought 39.10 01/28/17 | 49.40x |
| CIO | City Office REIT | Real Estate Investment Trust high quality Offices | 292 | 5.8 | 396Mln | 12.76 | Re Bought at 12.12 | 11.50x |
| TPC | Tutor Perini | Construction | 12 | 0.25 | 1.3B | 26.85 Stopped out 28.90 05/04 | 19.40 10/31/16 | Looking for place to buy |
| BMJ | Bristol Myers | Biopharmaceutical Products | 28 | 5.1 | 94.9B | 55.27 No position | Looking for place to buy | If bought sell at 53.90x |
| BA | Boeing | Aerospace, commercial jetliners, military systems | 14 | 0.85 | 81B | 241.27 | Long at 132 10/04/16 | We would raise stops to \$210 |
| HL | Hecla Mining | Basic Materials | 44 | 3.61 | 1.7B | 5.38 Look for re-entry | Long at 5.30 5/5/17 | A good long |
| FFIC | Flushing Financial | Bank Holding company Savings and loans | 13 | 3.5 | 592Mln | 28.38 | 19.10 06/27/16 | 50 day m.a. at 27.45 |
| AA | Alcoa | Aluminum Processing and Technology | N/A | 0.4 | 9.5B | 35.64 | 21.15 originally bought 2/8/16 | \$ 36.00 Sell short with stop at \$ 37 |
| ENZ | Enzo Biochem | Life Sciences | NA | 1.35 | 134M | 10.98 | Bought at 5.13 10/7/16 | <i>Sold on Opening Monday 4/3/17 Sold 8.43</i> |
| BAC | Bank of America | Commercial Bank | 10 | 2.02 | 165.3B | 23.80 | Bought at 15.42 9/30/16 | 23.60x stopped out on 3/21/17 |
| HDGE | Advisor Shares | Ranger Bear ETF | | | | 8.52 | <i>Sell stop at 8.34</i> | Must close above 8.48 to be long |

Mike King
Princeton Research
3887 Pacific Street, Las Vegas, Nevada 89121

Or: Charles Moskowitz
CAM@MoneyInfo-LLC.com
617 827 1296

Phone: (702) 650-3000
Fax: (702) 697-8944
mike@princetonresearch.com or cam@princetonresearch.com
Visit: www.princetonresearch.com

Disclaimer* Princeton is paid \$ 1,500 per month from RMS Medical Products. The SITS contract calls for \$ 1,500 per month. Princeton had been engaged by Target Energy. No contract is currently in place. . Princeton is paid \$ 2500 per month by Pressure Biosciences. Princeton was paid about 300,000 restricted shares of Leo Motors. Princeton is paid \$ 2,500 per month for International Star. Princeton is paid \$ 2,500 from Leo Motors. Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this Email issue. Princeton may buy or sell its free-trading shares in companies it represents at any time. Y means the writer has a position of 10,000 shares in the stock recommended.

UNSUBSCRIBE

To unsubscribe from this newsletter, please reply to this email with UNSUBSCRIBE in the subject line. We will send you a confirmation upon completing your request.